Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Clinical trials sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd., explained in plain language.
-
New inhaler shows promise for COPD in early trial
Disease control CompletedThis phase 2 trial tested an experimental inhaled powder called TQC3721 in 195 people with moderate to severe COPD. The goal was to see if it improves lung function and is safe compared to a placebo. Researchers measured changes in breathing capacity over four weeks.
Phase: PHASE2 • Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New pill for rare blood cancers shows promise in early trial
Disease control CompletedThis early-phase study tested a new drug called TQ05105 in 79 adults with certain blood cancers (myeloproliferative neoplasms). The main goals were to find the safest dose and understand side effects. The drug works by blocking a protein (JAK2) that can cause abnormal blood cell …
Phase: PHASE1 • Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New pill shows promise in shrinking spleens for myelofibrosis patients
Disease control CompletedThis study tested a new drug called TQ05105 in 107 people with moderate to high-risk myelofibrosis, a rare bone marrow disorder that often causes an enlarged spleen. The goal was to see if TQ05105 could shrink the spleen better than the standard drug hydroxyurea. Participants too…
Phase: PHASE2 • Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New drug combo shows promise against hard-to-treat breast cancer
Disease control CompletedThis study tested a new drug (TQB3616) combined with fulvestrant in 122 people with a type of advanced breast cancer (HR-positive, HER2-negative). The goal was to see if the combination could shrink tumors or slow the cancer's growth. Participants had either received one prior tr…
Phase: PHASE2 • Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New daily pill shows promise in early breast cancer trial
Disease control CompletedThis early-phase study tested a new daily pill called TQB3616 in 40 adults with advanced breast cancer that had stopped responding to standard hormone therapy. The pill works by blocking a protein that helps cancer cells multiply. The main goals were to find a safe dose and under…
Phase: PHASE1 • Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
New pill combo shows promise in slowing advanced breast cancer
Disease control CompletedThis study tested whether adding the experimental drug TQB3616 to standard hormone therapy (fulvestrant) can help slow cancer growth in people with a common type of advanced breast cancer (HR-positive, HER2-negative). About 293 women took part, receiving either the drug combo or …
Phase: PHASE3 • Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
New combo therapy shows promise for tough-to-treat nose and throat cancer
Disease control CompletedThis study tested a new drug combination (TQB2618 plus penpulimab) in 47 people with advanced nasopharyngeal carcinoma that had come back or spread. Some participants had already tried standard treatments, while others were new to therapy. The goal was to see if the combination w…
Phase: PHASE2 • Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New pill aims to silence hepatitis b virus in patients with stubborn Low-Level infection
Disease control CompletedThis study tested a new drug called TQA3605 in 122 adults with chronic hepatitis B who still had low levels of virus despite standard treatment. Participants took either TQA3605 or a placebo alongside their usual antiviral pills for 24 weeks. The goal was to see if adding TQA3605…
Phase: PHASE2 • Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:14 UTC
-
New hope for Hard-to-Treat thyroid cancer: experimental drug shows promise
Disease control CompletedThis early-phase trial tested an experimental drug called AL2846 in 33 people with a type of thyroid cancer that no longer responds to standard treatments. The goal was to see if the drug could shrink tumors or slow the cancer's growth. Participants took the drug by mouth, and do…
Phase: PHASE1, PHASE2 • Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
New antibody drug shows promise for severe asthma sufferers
Disease control CompletedThis study tested an experimental drug called TQC2731 in 205 adults with severe asthma that is not well controlled by standard treatments. The drug is a lab-made antibody that blocks a protein involved in asthma inflammation. Participants received either one of three doses of TQC…
Phase: PHASE2 • Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
New antibiotic TQD3524 tested in kidney patients
Knowledge-focused CompletedThis early-stage study tested a single dose of the antibiotic TQD3524 in 48 people with varying degrees of kidney function. The goal was to see how the drug moves through the body and is removed, especially by the kidneys, and to check for any safety issues. The study did not aim…
Phase: PHASE1 • Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:10 UTC
-
Kidney function affects new antibiotic breakdown
Knowledge-focused CompletedThis study looked at how the body processes an experimental antibiotic called TQD3606 in people with different levels of kidney function. 32 adults received a single dose, and researchers measured drug levels in blood and urine. The goal was to understand safety and drug clearanc…
Phase: PHASE1 • Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:09 UTC
-
Healthy volunteers help scientists trace Drug's path through the body
Knowledge-focused CompletedThis study gave a single dose of a radioactive-labeled drug, TQ05105, to 6 healthy Chinese men. Researchers measured how much of the drug left the body in urine and stool, and how it changed in the blood. The goal was to understand how the drug is broken down and removed, not to …
Phase: PHASE1 • Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:05 UTC
-
Generic platelet drug put to the test: will it match the original?
Knowledge-focused CompletedThis study checked whether a generic eltrombopag olamine tablet works the same as the brand-name version in 36 healthy Chinese adults after a meal. Participants took a single dose of each formulation in random order, and researchers measured how the drug moved through their bodie…
Phase: NA • Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:04 UTC
-
New drug interaction study for myelofibrosis treatment begins
Knowledge-focused CompletedThis phase 1 trial in 40 healthy adults tests how TQ05105, a drug for myelofibrosis, interacts with other medications that affect liver enzymes. Participants take TQ05105 alone and then with either itraconazole or rifampicin to see how these drugs change TQ05105 levels in the bod…
Phase: PHASE1 • Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:03 UTC